Earnings Sentiment

Sentiment Analysis of the earnings transcript to help figure out if there are any bullish or bearish sentiments that could be gathered from it. We're doing ML and AI based analysis on the earnings call to get some more insights.

Please consider a small donation if you think this website provides you with relevant information  

    

Sentiment Distribution

   

Earnings Call Transcript Word Cloud

     

Bullish Statements during Earnings call

Statement
In closing, we have a strong financial position to advance our mission, and we remain committed to developing our HBV assets to provide a functional cure for chronic HBV
Last June at EASL, we reported preliminary data that continues to reinforce our confidence in imdusiran's ability to effectively lower surface antigen
As we continue to advance the clinical development of imdusiran and AB-101, we believe both compounds are well positioned to deliver on our goal of developing a functional cure for hepatitis B and driving value for our company
We believe nivolumab may further boost the host immune response
I'm excited for my new role and plan to leverage my extensive scientific, strategic, transactional, and commercial experience with antiviral and infectious disease companies to continue to move Arbutus forward
In 2024, our focus is to position Arbutus for continued success and create value for all our stakeholders
All of our scientists take great pride in the intellectual property they develop which takes great effort, time, resources, and expense
There remains a need for finite and more efficacious HBV treatments that further improve long-term outcomes and increase functional cure rates as fewer than 5% of patients currently achieve functional cure with currently approved nukes or interferon
That said, our current strategy is evaluating imdusiran in combination with other agents in multiple Phase 2a clinical trials with the goal of gaining valuable insights on efficacy, safety, and optimal dosing to help inform the design of a Phase 2b clinical trial with imdusiran as the cornerstone therapy
As a Co-Founder of Arbutus, I am honored to have this opportunity to lead my colleagues in our mission to develop a functional cure for the millions of people chronically infected with hepatitis B virus
We take this, obviously, very seriously, we were pleased with the actual hearing itself, and we look forward to Justice Goldberg's ruling which we expect, as you know, within 60 days of February 8th
In 2023, we made several important strategic choices to best position Arbutus for long-term success
Importantly, we believe our cash runway is sufficient to fund our operations into the first quarter of 2026
We appreciate everyone's interest
Karen? Karen Sims Thanks Mike and good morning everyone
Dave? David Hastings Thanks Karen and good morning everybody
Good morning everyone and thank you for joining us today
And thanks everyone for joining us this morning
Dennis Ding Thank you
Achieving undetectable surface antigen levels in either of our current Phase 2a clinical trials would certainly be an important validation of imdusiran's role in potentially achieving the functional cure for hepatitis B patients
Thanks
Thanks
Thank you
Thank you
Thank you
Our goal is to develop a treatment for chronic hepatitis B virus patients that results in at least a 20% functional cure rate to address this large unmet medical need
Brian Skorney Hey, Good morning
       

Bearish Statements during earnings call

Statement
   

Please consider a small donation if you think this website provides you with relevant information